Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 11/2012

01-11-2012 | Review Article

Estrogen in obesity-associated colon cancer: friend or foe? Protecting postmenopausal women but promoting late-stage colon cancer

Authors: Jiezhong Chen, Don Iverson

Published in: Cancer Causes & Control | Issue 11/2012

Login to get access

Abstract

Obesity is associated with the increased incidence of colon cancer. Many cancer risk factors have been identified including increased blood levels of insulin, leptin, interleukin-6, interleukin-17, tumor necrosis factor-alpha, and decreased blood levels of adiponectin. However, the role of blood levels of estrogen in obesity-associated colon cancer is controversial. Evidence showed that obesity affected men more strongly than women in the carcinogenesis of colon cancer, indicating protective effect of estrogen which is increased in obesity. However, an epidemiological study has also shown that endogenous estradiol level is an independent risk factor for colon cancer, positively associated with colon cancer after normalizing insulin, IGF-1. The controversial opinions may be caused by different effects of ER-alpha and ER-beta. ER-alpha can increase colon cancer cell proliferation and increase cancer incidence. ER-beta has the opposite effect to ER-alpha, and it causes apoptosis of colon cancer cells. The normal colonocytes mainly express ER-beta. Therefore, increased estrogen in obesity may have protective effect via ER-beta in obesity-associated colon cancer. However, with the development of colon cancer, ER-alpha is increased and ER-beta is decreased. In the late stage of colon cancer, estrogen may promote cancer development via ER-alpha. The different effects and expression of ER-alpha and ER-beta may explain the different results observed in several epidemiological studies as well as several animal experiments. Therefore, manipulation of estrogen-caused signal pathways to inhibit ER-alpha and stimulate ER-beta may have preventive and therapeutic effect for obesity-associated colon cancer.
Literature
1.
Renehan AG et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578PubMedCrossRef
2.
Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–591PubMedCrossRef
3.
Gislette T, Chen J (2010) The possible role of IL-17 in obesity-associated cancer. Sci World J 10:2265–2271CrossRef
4.
Renehan AG et al (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353PubMedCrossRef
5.
Chen J et al (2011) Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3 K/Akt pathway. Curr Drug Discov Technol 8(2):119–125PubMedCrossRef
6.
Paz-Filho G et al (2011) Associations between adipokines and obesity-related cancer. Front Biosci 16:1634–1650PubMedCrossRef
7.
Renehan A, Dive C (2011) Obesity, insulin and chemoresistance in colon cancer. J Gastrointest Oncol 2(1):8–10PubMed
8.
Chen J et al (2011) Insulin caused drug resistance to oxaliplatin in colon cancer cell HT29. J Gastrointest Oncol 2:27–33PubMed
9.
10.
Huang XF, Chen J (2009) Obesity, the PI3 K/Akt signal pathway and colon cancer. Obes Rev 10(6):610–616PubMedCrossRef
11.
Chen J (2012) Targeted therapy of obesity-associated colon cancer. Transl Gastrointest Cancer 1(1):44–57
12.
Murphy TK et al (2000) Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol 152(9):847–854PubMedCrossRef
13.
Ben Q et al (2012) Body mass index increases risk for colorectal adenomas based on meta-analysis. Gastroenterology 142(4):762–772PubMedCrossRef
14.
Pischon T et al (2006) Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98(13):920–931PubMedCrossRef
15.
Kim BC et al (2012) Association of colorectal adenoma with components of metabolic syndrome. Cancer Causes Control 23(5):727–735PubMedCrossRef
16.
Terry PD, Miller AB, Rohan TE (2002) Obesity and colorectal cancer risk in women. Gut 51(2):191–194PubMedCrossRef
17.
Hou L et al (2006) Body mass index and colon cancer risk in Chinese people: menopause as an effect modifier. Eur J Cancer 42(1):84–90PubMedCrossRef
18.
Slattery ML et al (2001) Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res 61(1):126–130PubMed
19.
Sikalidis AK, Varamini B (2011) Roles of hormones and signalling molecules in describing the relationship between obesity and colon cancer. Pathol Oncol Res 17(4):785–790PubMedCrossRef
20.
Gunter MJ et al (2008) Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 68(1):329–337PubMedCrossRef
21.
English MA et al (1999) Loss of estrogen inactivation in colonic cancer. J Clin Endocrinol Metab 84(6):2080–2085PubMedCrossRef
22.
Lin J et al (2004) Body mass index and risk of colorectal cancer in women (United States). Cancer Causes Control 15(6):581–589PubMedCrossRef
23.
Di Domenico M et al (1996) Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res 56(19):4516–4521PubMed
24.
Narayan S et al (1992) Estradiol is trophic for colon cancer in mice: effect on ornithine decarboxylase and c-myc messenger RNA. Gastroenterology 103(6):1823–1832PubMed
25.
Rondini EA et al (2011) Energy balance modulates colon tumour growth: interactive roles of insulin and estrogen. Mol Carcinog 50(5):370–382PubMedCrossRef
26.
Enmark E et al (1997) Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82(12):4258–4265PubMedCrossRef
27.
Menasce LP et al (1993) Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 17(1):263–265PubMedCrossRef
28.
Motylewska E, Stasikowska O, Melen-Mucha G (2009) The inhibitory effect of diarylpropionitrile, a selective agonist of estrogen receptor beta, on the growth of MC38 colon cancer line. Cancer Lett 276(1):68–73PubMedCrossRef
29.
Greene GL et al (1986) Sequence and expression of human estrogen receptor complementary DNA. Science 231(4742):1150–1154PubMedCrossRef
30.
Cho MA et al (2007) Expression and role of estrogen receptor alpha and beta in medullary thyroid carcinoma: different roles in cancer growth and apoptosis. J Endocrinol 195(2):255–263PubMedCrossRef
31.
Chow SK, Chan JY, Fung KP (2004) Suppression of cell proliferation and regulation of estrogen receptor alpha signalling pathway by arsenic trioxide on human breast cancer MCF-7 cells. J Endocrinol 182(2):325–337PubMedCrossRef
32.
Nilsson S et al (2001) Mechanisms of estrogen action. Physiol Rev 81(4):1535–1565PubMed
33.
de Batistuzzo Medeiros SR (1997) Functional interactions between the estrogen receptor and the transcription activator Sp1 regulate the estrogen-dependent transcriptional activity of the vitellogenin A1 io promoter. J Biol Chem 272(29):18250–18260CrossRef
34.
Porter W et al (1997) Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 11(11):1569–1580PubMedCrossRef
35.
Qin C, Singh P, Safe S (1999) Transcriptional activation of insulin-like growth factor-binding protein-4 by 17beta-estradiol in MCF-7 cells: role of estrogen receptor-Sp1 complexes. Endocrinology 140(6):2501–2508PubMedCrossRef
36.
Webb P et al (1999) The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 13(10):1672–1685PubMedCrossRef
37.
Wang C et al (2011) Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol 25(9):1527–1538PubMedCrossRef
38.
Bjornstrom L, Sjoberg M (2005) Mechanisms of estrogen receptor signalling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19(4):833–842PubMedCrossRef
39.
Hewitt SC et al (2005) Global uterine genomics in vivo: microarray evaluation of the estrogen receptor alpha-growth factor cross-talk mechanism. Mol Endocrinol 19(3):657–668PubMedCrossRef
40.
Simoncini T et al (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407(6803):538–541PubMedCrossRef
41.
Le Romancer M et al (2008) Regulation of estrogen rapid signalling through arginine methylation by PRMT1. Mol Cell 31(2):212–221PubMedCrossRef
42.
Yang Z, Barnes CJ, Kumar R (2004) Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 10(11):3621–3628PubMedCrossRef
43.
Duan R et al (2001) Estrogen receptor-mediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1. J Biol Chem 276(15):11590–11598PubMedCrossRef
44.
Acconcia F et al (2005) Survival versus apoptotic 17beta-estradiol effect: role of ER alpha and ER beta activated non-genomic signalling. J Cell Physiol 203(1):193–201PubMedCrossRef
45.
La Rosa P et al (2011) 17beta-Estradiol-induced cell proliferation requires estrogen receptor (ER) alpha monoubiquitination. Cell Signal 23(7):1128–1135PubMedCrossRef
46.
Marino M, Acconcia F, Trentalance A (2003) Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol Biol Cell 14(6):2583–2591PubMedCrossRef
47.
Song RX et al (2004) The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci USA 101(7):2076–2081PubMedCrossRef
48.
Zhang Z et al (2004) The role of adapter protein Shc in estrogen non-genomic action. Steroids 69(8–9):523–529PubMedCrossRef
49.
Fernando RI, Wimalasena J (2004) Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signalling through ERK and Akt. Mol Biol Cell 15(7):3266–3284PubMedCrossRef
50.
Marino M et al (2002) Distinct nongenomic signal transduction pathways controlled by 17beta-estradiol regulate DNA synthesis and cyclin D(1) gene transcription in HepG2 cells. Mol Biol Cell 13(10):3720–3729PubMedCrossRef
51.
Bredfeldt TG et al (2010) Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signalling to PI3 K/AKT. Mol Endocrinol 24(5):993–1006PubMedCrossRef
52.
Gustafsson JA (1999) Estrogen receptor beta—a new dimension in estrogen mechanism of action. J Endocrinol 163(3):379–383PubMedCrossRef
53.
Kuiper GG et al (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93(12):5925–5930PubMedCrossRef
54.
Zhao C, Dahlman-Wright K, Gustafsson JA (2010) Estrogen signalling via estrogen receptor {beta}. J Biol Chem 285(51):39575–39579PubMedCrossRef
55.
Galluzzo P et al (2007) Role of ERbeta palmitoylation in the inhibition of human colon cancer cell proliferation. Endocr Relat Cancer 14(1):153–167PubMedCrossRef
56.
Weige CC, Allred KF, Allred CD (2009) Estradiol alters cell growth in nonmalignant colonocytes and reduces the formation of preneoplastic lesions in the colon. Cancer Res 69(23):9118–9124PubMedCrossRef
57.
Edvardsson K et al (2011) Estrogen receptor beta induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol 25(6):969–979PubMedCrossRef
58.
59.
Dhanasekaran DN, Johnson GL (2007) MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene 26(22):3097–3099PubMedCrossRef
60.
Cuenda A, Rousseau S (2007) p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773(8):1358–1375PubMedCrossRef
61.
Porras A et al (2004) P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell 15(2):922–933PubMedCrossRef
62.
Hui L et al (2007) p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 6(20):2429–2433PubMedCrossRef
63.
Shimada K et al (2003) Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24(6):1067–1075PubMedCrossRef
64.
Hui L et al (2007) p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 39(6):741–749PubMedCrossRef
65.
Iwasa H, Han J, Ishikawa F (2003) Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway. Genes Cells 8(2):131–144PubMedCrossRef
66.
Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK (2004) Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 64(20):7336–7345PubMedCrossRef
67.
Feng Y, Wen J, Chang CC (2009) p38 Mitogen-activated protein kinase and hematologic malignancies. Arch Pathol Lab Med 133(11):1850–1856PubMed
68.
Gompel A et al (2004) Steroidal hormones and proliferation, differentiation and apoptosis in breast cells. Maturitas 49(1):16–24PubMedCrossRef
69.
Lin JH et al (2012) Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression. Cancer Res 72(12):3020–3028PubMedCrossRef
70.
Tanaka Y et al (2008) Medroxyprogesterone acetate inhibits proliferation of colon cancer cell lines by modulating cell cycle-related protein expression. Menopause 15(3):442–453PubMedCrossRef
71.
Gizard F et al (2005) Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene. FEBS Lett 579(25):5535–5541PubMedCrossRef
72.
Konstantinopoulos PA et al (2003) Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer 39(9):1251–1258PubMedCrossRef
73.
Qiu Y et al (2002) Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. J Endocrinol 174(3):369–377PubMedCrossRef
74.
Jassam N et al (2005) Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes’ staging. Oncol Rep 14(1):17–21PubMed
75.
Fang YJ et al (2010) Prognostic impact of ERbeta and MMP7 expression on overall survival in colon cancer. Tumour Biol 31(6):651–658PubMedCrossRef
76.
Wong NA et al (2005) ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol 207(1):53–60PubMedCrossRef
77.
Wu AH et al (2010) Hormone therapy, DNA methylation and colon cancer. Carcinogenesis 31(6):1060–1067PubMedCrossRef
78.
Lin KJ et al (2012) The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 130(2):419–430PubMedCrossRef
79.
Hiraoka S et al (2010) Methylation status of normal background mucosa is correlated with occurrence and development of neoplasia in the distal colon. Hum Pathol 41(1):38–47PubMedCrossRef
80.
Anghel A et al (2010) Estrogen receptor alpha polymorphisms and the risk of malignancies. Pathol Oncol Res 16(4):485–496PubMedCrossRef
81.
Worthley DL et al (2010) DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene 29(11):1653–1662PubMedCrossRef
82.
Honma et al (2012) Estrogen receptor-beta gene polymorphism and colorectal cancer risk: effect modified by body mass index and isoflavone intake. Int J Cancer
83.
Saleiro et al (2012) Estrogen receptor-beta protects against colitis-associated neoplasia in mice. Int J Cancer
84.
Gallo D et al (2012) Estrogen receptor beta in cancer: an attractive target for therapy. Curr Pharm Des 18(19):2734–2757PubMedCrossRef
85.
Yi KW et al (2008) Role of estrogen receptor-alpha and -beta in regulating leptin expression in 3T3-L1 adipocytes. Obes (Silver Spring) 16(11):2393–2399CrossRef
86.
Nejati-Koshki et al (2012) Inhibition of leptin gene expression and secretion by silibinin: possible role of estrogen receptors. Cytotechnology
87.
Mendoza RA et al (2011) Interactions between IGF-I, estrogen receptor-alpha (ERalpha), and ERbeta in regulating growth/apoptosis of MCF-7 human breast cancer cells. J Endocrinol 208(1):1–9PubMedCrossRef
88.
Harris DM et al (2005) Phytoestrogens induce differential estrogen receptor alpha- or Beta-mediated responses in transfected breast cancer cells. Exp Biol Med (Maywood) 230(8):558–568
89.
Schleipen B et al (2011) ERbeta-specific agonists and genistein inhibit proliferation and induce apoptosis in the large and small intestine. Carcinogenesis 32(11):1675–1683PubMedCrossRef
90.
Bielecki A et al (2011) Estrogen receptor-beta mediates the inhibition of DLD-1 human colon adenocarcinoma cells by soy isoflavones. Nutr Cancer 63(1):139–150PubMed
91.
Cotterchio M et al (2006) Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. J Nutr 136(12):3046–3053PubMed
92.
Yang G et al (2009) Prospective cohort study of soy food intake and colorectal cancer risk in women. Am J Clin Nutr 89(2):577–583PubMedCrossRef
93.
Tu Z et al (2012) Estrogen receptor beta potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells. J Cancer Res Clin Oncol 138(7):1091–1103PubMedCrossRef
Metadata
Title
Estrogen in obesity-associated colon cancer: friend or foe? Protecting postmenopausal women but promoting late-stage colon cancer
Authors
Jiezhong Chen
Don Iverson
Publication date
01-11-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 11/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0066-z

Other articles of this Issue 11/2012

Cancer Causes & Control 11/2012 Go to the issue

Original paper

Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women

Original paper

NQO1 rs1800566 (C609T), PON1 rs662 (Q192R), and PON1 rs854560 (L55M) polymorphisms segregate the risk of childhood acute leukemias according to age range distribution

Original paper

ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium

Original paper

Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review

Review article

Critical review and synthesis of the epidemiologic evidence on formaldehyde exposure and risk of leukemia and other lymphohematopoietic malignancies

Original paper

Intake of omega-3 and omega-6 fatty acids and risk of ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits